Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

NCT06510309 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Marginal Zone Lymphoma
MZL

Interventions

DRUG: Venetoclax
DRUG: Rituximab

Sponsor

Gottfried von Keudell, MD PhD

Collaborators

[object Object]